[S02DA03, antipyrine, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Streptokinase.]
[J01GA01, streptomycin, Levomilnacipran may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Levomilnacipran.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01CG01, sulbactam, Levomilnacipran may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Sulfamethoxazole.]
[M04AB02, sulfinpyrazone, The metabolism of Levomilnacipran can be increased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Sulindac.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Levomilnacipran.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Sulthiame is combined with Levomilnacipran.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Glymidine.]
[M01AX04, apazone, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Azapropazone.]
[L02BA01, tamoxifen, The metabolism of Levomilnacipran can be increased when combined with Tamoxifen.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Levomilnacipran.]
[R03CC03, terbutaline, Levomilnacipran may increase the tachycardic activities of Terbutaline.]
[B01AE07, dabigatran etexilate, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Dabigatran etexilate.]
[G03BA03, testosterone, The metabolism of Levomilnacipran can be increased when combined with Testosterone.]
[N07XX06, tetrabenazine, The metabolism of Levomilnacipran can be decreased when combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Tetracaine is combined with Levomilnacipran.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Lurasidone is combined with Levomilnacipran.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Levomilnacipran.]
[L04AX02, thalidomide, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Levomilnacipran.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Levomilnacipran.]
[N05CA19, thiopental, The metabolism of Levomilnacipran can be increased when combined with Thiopental.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Thioproperazine is combined with Levomilnacipran.]
[N05AC02, thioridazine, The metabolism of Levomilnacipran can be decreased when combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Thiothixene is combined with Levomilnacipran.]
[C01BB04, aprindine, The metabolism of Levomilnacipran can be decreased when combined with Aprindine.]
[G04BE06, moxisylyte, Levomilnacipran may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Levomilnacipran.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Levomilnacipran.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Tiapride is combined with Levomilnacipran.]
[B01AC05, ticlopidine, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of serotonin syndrome can be increased when Tilidine is combined with Levomilnacipran.]
[S01ED01, timolol, The serum concentration of Timolol can be increased when it is combined with Levomilnacipran.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[S01AA12, tobramycin, Levomilnacipran may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Tolazamide.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Tolmetin.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Tolperisone is combined with Levomilnacipran.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Levomilnacipran is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the serotonergic activities of Levomilnacipran.]
[C01DX11, trapidil, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Trapidil.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Levomilnacipran.]
[L01XF01, tretinoin, The metabolism of Levomilnacipran can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The metabolism of Levomilnacipran can be increased when combined with Triamcinolone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Levomilnacipran.]
[C03AA06, trichlormethiazide, The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Trichlormethiazide.]
[A03AB12, mepenzolate, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[A16AX12, trientine, Triethylenetetramine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levomilnacipran.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Trifluperidol is combined with Levomilnacipran.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Levomilnacipran.]
[N04AA01, trihexyphenidyl, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[R03BA07, mometasone, The metabolism of Levomilnacipran can be increased when combined with Mometasone.]
[A03AA05, trimebutine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Alimemazine is combined with Levomilnacipran.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Levomilnacipran.]
[J01EA01, trimethoprim, The metabolism of Levomilnacipran can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Levomilnacipran.]
[R06AC04, tripelennamine, The metabolism of Levomilnacipran can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Levomilnacipran.]
[A03BB01, butylscopolamine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Levomilnacipran can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Levomilnacipran can be decreased when combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Levomilnacipran.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Levomilnacipran.]
[R03DX07, roflumilast, Roflumilast may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L01FX04, ipilimumab, Ipilimumab may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[R02AA14, oxyquinoline, Levomilnacipran may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Levomilnacipran can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Levomilnacipran can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Levomilnacipran can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Levomilnacipran can be decreased when combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Urokinase.]
[S01AA28, vancomycin, Levomilnacipran may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Ezogabine is combined with Levomilnacipran.]
[B01AF01, rivaroxaban, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Rivaroxaban.]
[R03AC18, indacaterol, Levomilnacipran may increase the tachycardic activities of Indacaterol.]
[B01AC24, ticagrelor, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Levomilnacipran can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Levomilnacipran can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Levomilnacipran can be increased when combined with Vinblastine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[A11HA03, vitamin E, The metabolism of Levomilnacipran can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Warfarin.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The metabolism of Levomilnacipran can be decreased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levomilnacipran.]
[J05AE02, indinavir, The metabolism of Levomilnacipran can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Levomilnacipran.]
[L01EC01, vemurafenib, The metabolism of Levomilnacipran can be increased when combined with Vemurafenib.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[B06AC02, icatibant, Icatibant may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L01ED01, crizotinib, The metabolism of Levomilnacipran can be decreased when combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Lepirudin.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Deferiprone may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N02BA01, aspirin, Levomilnacipran may increase the antiplatelet activities of Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Ruxolitinib may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[G04BD07, tolterodine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J01DH04, doripenem, Doripenem may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C07AB03, atenolol, The serum concentration of Atenolol can be increased when it is combined with Levomilnacipran.]
[J02AC03, voriconazole, The metabolism of Levomilnacipran can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Atracurium is combined with Levomilnacipran.]
[S01FA01, atropine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[B03XA04, peginesatide, Peginesatide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L04AX01, azathioprine, Azathioprine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Levomilnacipran.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.]
[A08AA11, lorcaserin, The metabolism of Levomilnacipran can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Levomilnacipran can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Levomilnacipran can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Levomilnacipran can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Levomilnacipran can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Levomilnacipran can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, The metabolism of Levomilnacipran can be decreased when combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Defibrotide.]
[C01CA18, octopamine, Levomilnacipran may increase the tachycardic activities of Octopamine.]
[N05CA04, barbital, The metabolism of Levomilnacipran can be increased when combined with Barbital.]
[D02BA02, octinoxate, Levomilnacipran may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Levomilnacipran can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.]
[N04BD02, rasagiline, Rasagiline may increase the serotonergic activities of Levomilnacipran.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Mosapride is combined with Levomilnacipran.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Levomilnacipran.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.]
[N02CC03, zolmitriptan, The risk or severity of serotonin syndrome can be increased when Levomilnacipran is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Levomilnacipran can be decreased when combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Levomilnacipran may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Diethyl ether is combined with Levomilnacipran.]
[L01EX07, cabozantinib, The metabolism of Levomilnacipran can be decreased when combined with Cabozantinib.]
[H01CB05, pasireotide, The risk or severity of hypoglycemia can be increased when Pasireotide is combined with Levomilnacipran.]
[G04BE03, sildenafil, The metabolism of Levomilnacipran can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Gadofosveset trisodium may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Levomilnacipran.]
[B01AF02, apixaban, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Apixaban.]
[A16AX08, teduglutide, Teduglutide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[A10BH04, alogliptin, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Levomilnacipran can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Levomilnacipran.]
[G03XC05, ospemifene, The metabolism of Levomilnacipran can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Benperidol is combined with Levomilnacipran.]
[A10BK02, canagliflozin, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Canagliflozin.]
[A06AX06, tegaserod, The metabolism of Levomilnacipran can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Levomilnacipran.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Insulin detemir.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Benzocaine is combined with Levomilnacipran.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Pramlintide.]
[L03AA12, ancestim, Levomilnacipran may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of bleeding can be increased when Celecoxib is combined with Levomilnacipran.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Levomilnacipran.]
[L04AA18, everolimus, The metabolism of Levomilnacipran can be decreased when combined with Everolimus.]
[N04AC01, benztropine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Levomilnacipran can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Benzydamine.]
[L01EE01, trametinib, The metabolism of Levomilnacipran can be increased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Levomilnacipran.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Levomilnacipran.]
[V09AX05, florbetapir F-18, Levomilnacipran may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[S01AA13, fusidic acid, The metabolism of Levomilnacipran can be decreased when combined with Fusidic acid.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C08EA02, bepridil, The metabolism of Levomilnacipran can be decreased when combined with Bepridil.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Levomilnacipran.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Lixisenatide.]
[C02KX04, macitentan, Levomilnacipran may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Levomilnacipran.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Vortioxetine is combined with Levomilnacipran.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The metabolism of Levomilnacipran can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Levomilnacipran can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Levomilnacipran may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Levomilnacipran.]
[A10BK01, dapagliflozin, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Dapagliflozin.]
[C01CA27, droxidopa, Levomilnacipran may increase the tachycardic activities of Droxidopa.]
[C07AB04, acebutolol, The serum concentration of Acebutolol can be increased when it is combined with Levomilnacipran.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Tasimelteon is combined with Levomilnacipran.]
[A16AA07, metreleptin, The metabolism of Levomilnacipran can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Levomilnacipran can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Levomilnacipran can be increased when combined with Formestane.]
[S03BA03, betamethasone, The metabolism of Levomilnacipran can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The serum concentration of Betaxolol can be increased when it is combined with Levomilnacipran.]
[B01AE03, argatroban, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Argatroban.]
[V03AB34, fomepizole, Fomepizole may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C02CC01, bethanidine, Levomilnacipran may increase the tachycardic activities of Bethanidine.]
[C10AB02, bezafibrate, The metabolism of Levomilnacipran can be decreased when combined with Bezafibrate.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Albiglutide.]
[L04AC11, siltuximab, The metabolism of Levomilnacipran can be increased when combined with Siltuximab.]
[B01AC26, vorapaxar, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Vorapaxar.]
[A03BA03, hyoscyamine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Acenocoumarol.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Alfaxalone is combined with Levomilnacipran.]
[A10BK03, empagliflozin, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Empagliflozin.]
[R03AC19, olodaterol, Levomilnacipran may increase the tachycardic activities of Olodaterol.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[D11AA01, glycopyrronium, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05CM19, suvorexant, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Levomilnacipran can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Levomilnacipran can be increased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Acepromazine is combined with Levomilnacipran.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Dulaglutide.]
[A06AH03, naloxegol, The risk or severity of serotonin syndrome can be increased when Naloxegol is combined with Levomilnacipran.]
[N04AA02, biperiden, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Levomilnacipran can be decreased when combined with Pirfenidone.]
[S03AA06, gentamicin, Levomilnacipran may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Levomilnacipran.]
[B01AA01, dicumarol, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Edoxaban.]
[N06AX11, mirtazapine, Levomilnacipran may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Levomilnacipran can be increased when combined with Secukinumab.]
[L01XH03, panobinostat, The metabolism of Levomilnacipran can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Levomilnacipran can be increased when combined with Acetaminophen.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[A03AA09, difemerine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Tioclomarol.]
[J05AP06, asunaprevir, The metabolism of Levomilnacipran can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Eluxadoline is combined with Levomilnacipran.]
[B01AC25, cangrelor, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Cangrelor.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Levomilnacipran.]
[A04AD14, rolapitant, The metabolism of Levomilnacipran can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Flibanserin is combined with Levomilnacipran.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Cariprazine is combined with Levomilnacipran.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Acarbose.]
[M02AA25, aceclofenac, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Levomilnacipran.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Insulin degludec.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Levomilnacipran.]
[A02BC03, lansoprazole, The metabolism of Levomilnacipran can be increased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Levomilnacipran may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Levomilnacipran.]
[J02AC05, isavuconazole, The metabolism of Levomilnacipran can be increased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Levomilnacipran.]
[L01XG03, ixazomib, Levomilnacipran may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Levomilnacipran.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Acetohexamide.]
[M04AB05, lesinurad, Levomilnacipran may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, The metabolism of Levomilnacipran can be increased when combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Brivaracetam is combined with Levomilnacipran.]
[L01XX52, venetoclax, The metabolism of Levomilnacipran can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Levomilnacipran.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Levomilnacipran.]
[A02AD05, aluminum magnesium silicate, Levomilnacipran may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Levomilnacipran.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levomilnacipran.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Amineptine is combined with Levomilnacipran.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Aniracetam is combined with Levomilnacipran.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Levomilnacipran.]
[C07AA19, bupranolol, The serum concentration of Bupranolol can be increased when it is combined with Levomilnacipran.]
[N07BC01, buprenorphine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Levomilnacipran.]
[L01XX27, arsenic trioxide, Arsenic trioxide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[P01BE02, artemether, The metabolism of Levomilnacipran can be increased when combined with Artemether.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N02AF01, butorphanol, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Levomilnacipran.]
[S01GX07, azelastine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Levomilnacipran can be decreased when combined with Rucaparib.]
[L01EF02, ribociclib, The metabolism of Levomilnacipran can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Balsalazide.]
[R03CC12, bambuterol, Levomilnacipran may increase the tachycardic activities of Bambuterol.]
[A06AH05, naldemedine, Levomilnacipran may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Levomilnacipran may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The therapeutic efficacy of Levomilnacipran can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Beclamide is combined with Levomilnacipran.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Benfluorex.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Levomilnacipran.]
[D05AX03, calcitriol, The metabolism of Levomilnacipran can be increased when combined with Calcitriol.]
[P01CA02, benznidazole, Levomilnacipran may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Levomilnacipran.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Levomilnacipran can be decreased when combined with Tipranavir.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Levomilnacipran.]
[N07XX13, valbenazine, Levomilnacipran may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Levomilnacipran can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Levomilnacipran can be decreased when combined with Midostaurin.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Levomilnacipran.]
[L01ED04, brigatinib, The metabolism of Levomilnacipran can be increased when combined with Brigatinib.]
[N04BD03, safinamide, Safinamide may increase the serotonergic activities of Levomilnacipran.]
[L04AC14, sarilumab, The metabolism of Levomilnacipran can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, The metabolism of Levomilnacipran can be increased when combined with Delafloxacin.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Levomilnacipran.]
[L01BC06, capecitabine, Capecitabine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L01XX59, enasidenib, The metabolism of Levomilnacipran can be increased when combined with Enasidenib.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Levomilnacipran.]
[R03AC17, bitolterol, Levomilnacipran may increase the tachycardic activities of Bitolterol.]
[J05AG03, efavirenz, The metabolism of Levomilnacipran can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C07AA17, bopindolol, The serum concentration of Bopindolol can be increased when it is combined with Levomilnacipran.]
[N04AA11, bornaprine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Bromperidol is combined with Levomilnacipran.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Brotizolam is combined with Levomilnacipran.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The metabolism of Levomilnacipran can be increased when combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Levomilnacipran.]
[J05AX18, letermovir, The metabolism of Levomilnacipran can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Butriptyline is combined with Levomilnacipran.]
[C01AA02, acetyldigoxins, The risk or severity of hypotension can be increased when Levomilnacipran is combined with Acetyldigoxin.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Semaglutide.]
[A10BK04, ertugliflozin, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Ertugliflozin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Vinylbital is combined with Levomilnacipran.]
[R06AX18, acrivastine, Levomilnacipran may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[L02BB05, apalutamide, The metabolism of Levomilnacipran can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Levomilnacipran can be increased when combined with Carbamazepine.]
[A03AA03, camylofine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[H03BB01, carbimazole, The therapeutic efficacy of Carbimazole can be decreased when used in combination with Levomilnacipran.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levomilnacipran.]
[C07AG02, carvedilol, The serum concentration of Carvedilol can be increased when it is combined with Levomilnacipran.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Levomilnacipran.]
[B02BX08, avatrombopag, The metabolism of Levomilnacipran can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, Levomilnacipran may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Levomilnacipran.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01GB14, plazomicin, Levomilnacipran may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The serum concentration of Celiprolol can be increased when it is combined with Levomilnacipran.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Levomilnacipran.]
[L01XX62, ivosidenib, The metabolism of Levomilnacipran can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Levomilnacipran can be decreased when combined with Tafenoquine.]
[A16AX14, migalastat, Migalastat may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Levomilnacipran can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Levomilnacipran can be increased when combined with Tecovirimat.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Levomilnacipran.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Levomilnacipran.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Carbromal is combined with Levomilnacipran.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Carbutamide.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levomilnacipran.]
[D08AE05, chloroxylenol, Levomilnacipran may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Lornoxicam.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Levomilnacipran.]
[R03BB08, revefenacin, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01ED05, lorlatinib, The metabolism of Levomilnacipran can be increased when combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Levomilnacipran can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L01EX13, gilteritinib, The therapeutic efficacy of Levomilnacipran can be decreased when used in combination with Gilteritinib.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be decreased when combined with Levomilnacipran.]
[A06AX05, prucalopride, Prucalopride may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Cibenzoline.]
[B01AX07, caplacizumab, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Caplacizumab.]
[B01AC23, cilostazol, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Cilostazol.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Cinitapride is combined with Levomilnacipran.]
[P02BX04, triclabendazole, The metabolism of Levomilnacipran can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Esketamine.]
[J01FA09, clarithromycin, The metabolism of Levomilnacipran can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Levomilnacipran.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Brexanolone is combined with Levomilnacipran.]
[N05BA09, clobazam, The metabolism of Levomilnacipran can be decreased when combined with Clobazam.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Levomilnacipran.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Ubidecarenone.]
[C09CA06, candesartan, The metabolism of Levomilnacipran can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Levomilnacipran can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The metabolism of Levomilnacipran can be increased when combined with Alpelisib.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Cyamemazine is combined with Levomilnacipran.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Levomilnacipran.]
[L01EJ02, fedratinib, The metabolism of Levomilnacipran can be decreased when combined with Fedratinib.]
[N07XX11, pitolisant, The serum concentration of Levomilnacipran can be decreased when it is combined with Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Levomilnacipran.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Levomilnacipran.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Insulin pork.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01DB09, cephradine, The metabolism of Levomilnacipran can be increased when combined with Cefradine.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Levomilnacipran.]
[N03AX25, cenobamate, The serum concentration of Levomilnacipran can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Levomilnacipran can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Levomilnacipran may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levomilnacipran.]
[R06AB02, dexchlorpheniramine, The metabolism of Levomilnacipran can be decreased when combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Levomilnacipran may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of serotonin syndrome can be increased when Dezocine is combined with Levomilnacipran.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Lemborexant is combined with Levomilnacipran.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lumateperone is combined with Levomilnacipran.]
[M01AX21, diacetylrhein, The metabolism of Levomilnacipran can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of hypoglycemia can be increased when Gatifloxacin is combined with Levomilnacipran.]
[H02CA02, osilodrostat, The metabolism of Levomilnacipran can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Levomilnacipran can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Levomilnacipran.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Levomilnacipran.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Levomilnacipran.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Levomilnacipran.]
[R02AA03, dichlorobenzyl alcohol, Levomilnacipran may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Levomilnacipran may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Levomilnacipran.]
[N02AA08, dihydrocodeine, The risk or severity of serotonin syndrome can be increased when Dihydrocodeine is combined with Levomilnacipran.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Levomilnacipran.]
[M01AH02, rofecoxib, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Levomilnacipran can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Levomilnacipran can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Levomilnacipran can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Valpromide is combined with Levomilnacipran.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levomilnacipran.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Levomilnacipran.]
[A03AA08, dihexyverine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[C01CA14, dopexamine, Levomilnacipran may increase the tachycardic activities of Dopexamine.]
[G04BD09, trospium, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Droxicam.]
[V08CA05, mangafodipir, Mangafodipir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L01EX22, selpercatinib, The serum concentration of Levomilnacipran can be increased when it is combined with Selpercatinib.]
[B01AE02, lepirudin, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Clomethiazole is combined with Levomilnacipran.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Levomilnacipran.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Levomilnacipran.]
[P01BB01, proguanil, The metabolism of Levomilnacipran can be decreased when combined with Proguanil.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Remimazolam is combined with Levomilnacipran.]
[N07XX04, sodium oxybate, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[L04AC19, satralizumab, The serum concentration of Levomilnacipran can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Levomilnacipran is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Levomilnacipran can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Levomilnacipran can be increased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Levomilnacipran.]
[N05AA01, chlorpromazine, The metabolism of Levomilnacipran can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Chlorpropamide.]
[N05AF03, chlorprothixene, The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Levomilnacipran.]
[C03BA04, chlorthalidone, The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Chlorthalidone.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levomilnacipran.]
[A11CC05, cholecalciferol, The metabolism of Levomilnacipran can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Etifoxine is combined with Levomilnacipran.]
[N02BA07, ethenzamide, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Ethenzamide.]
[N02BA03, choline salicylate, Levomilnacipran may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Vinpocetine is combined with Levomilnacipran.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Levomilnacipran.]
[M01AB08, etodolac, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Levomilnacipran can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Levomilnacipran can be decreased when combined with Lonafarnib.]
[M01AX25, chondroitin sulfates, Levomilnacipran may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[P03AX07, abametapir, The serum concentration of Levomilnacipran can be increased when it is combined with Abametapir.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Febarbamate is combined with Levomilnacipran.]
[N03AX10, felbamate, The metabolism of Levomilnacipran can be increased when combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Fenbufen.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N06BA08, fenozolone, The risk or severity of Tachycardia can be increased when Levomilnacipran is combined with Fenozolone.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[R03BA03, flunisolide, The metabolism of Levomilnacipran can be increased when combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The metabolism of Levomilnacipran can be increased when combined with Fluocinolone acetonide.]
[N02BG07, flupirtine, Flupirtine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[R03CC15, formoterol, Levomilnacipran may increase the tachycardic activities of Formoterol.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Insulin human.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Levomilnacipran.]
[L03AB10, peginterferon alfa-2b, The metabolism of Levomilnacipran can be decreased when combined with Peginterferon alfa-2b.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Levomilnacipran.]
[A02BA01, cimetidine, The metabolism of Levomilnacipran can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Levomilnacipran.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N07CA02, cinnarizine, The metabolism of Levomilnacipran can be decreased when combined with Cinnarizine.]
[L01XX73, sotorasib, The serum concentration of Levomilnacipran can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Levomilnacipran can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Levomilnacipran may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Citalopram is combined with Levomilnacipran.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Levomilnacipran.]
[V09AX06, florbetaben f-18, Levomilnacipran may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Levomilnacipran.]
[M01AG01, mefenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Mefenamic acid.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Glimepiride.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Gliquidone.]
[R03CC13, clenbuterol, Levomilnacipran may increase the tachycardic activities of Clenbuterol.]
[N06AX25, St. John's wort extract, The metabolism of Levomilnacipran can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Levomilnacipran.]
[B01AD11, tenecteplase, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Tenecteplase.]
[C10AB01, clofibrate, The metabolism of Levomilnacipran can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Levomilnacipran can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Levomilnacipran.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Clomipramine is combined with Levomilnacipran.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Levomilnacipran.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Levomilnacipran.]
[C01EB24, mavacamten, The serum concentration of Levomilnacipran can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Tirzepatide.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Clothiapine is combined with Levomilnacipran.]
[H01CC04, linzagolix, The serum concentration of Levomilnacipran can be increased when it is combined with Linzagolix.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Levomilnacipran.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Levomilnacipran.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Levomilnacipran.]
[N05AH02, clozapine, The metabolism of Levomilnacipran can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Sotagliflozin.]
[J01GB12, arbekacin, Levomilnacipran may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Levomilnacipran.]
[H01AC08, somatrogon, The metabolism of Levomilnacipran can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, The risk or severity of extrapyramidal symptoms can be increased when Metyrosine is combined with Levomilnacipran.]
[L04AC21, bimekizumab, The metabolism of Levomilnacipran can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of serotonin syndrome can be increased when Codeine is combined with Levomilnacipran.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Levomilnacipran.]
[M04AC01, colchicine, Colchicine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[A03AB10, hexocyclium, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, Levomilnacipran may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Levomilnacipran.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Tropisetron is combined with Levomilnacipran.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Ifenprodil is combined with Levomilnacipran.]
[A10BX03, nateglinide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Levomilnacipran can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Levomilnacipran can be decreased when combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Levomilnacipran.]
[J05AB14, valganciclovir, Valganciclovir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C05BB03, invert sugar, Levomilnacipran may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Iodixanol may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[V08AB05, iopromide, Levomilnacipran may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Levomilnacipran may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Levomilnacipran may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Valdecoxib.]
[H01AX01, pegvisomant, The metabolism of Levomilnacipran can be increased when combined with Pegvisomant.]
[A03AX10, isometheptene, Levomilnacipran may increase the tachycardic activities of Isometheptene.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Levomilnacipran.]
[M01AH04, parecoxib, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Levomilnacipran can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Bemiparin.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Ketazolam is combined with Levomilnacipran.]
[M01AA06, kebuzone, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Levomilnacipran can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Levomilnacipran can be decreased when combined with Posaconazole.]
[N03AX09, lamotrigine, The risk or severity of adverse effects can be increased when Lamotrigine is combined with Levomilnacipran.]
[S01GX02, levocabastine, The risk or severity of adverse effects can be increased when Levocabastine is combined with Levomilnacipran.]
[N07BC04, lofexidine, The therapeutic efficacy of Levomilnacipran can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Lonazolac.]
[R06AX13, loratadine, The metabolism of Levomilnacipran can be decreased when combined with Loratadine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Lormetazepam is combined with Levomilnacipran.]
[M02AA31, loxoprofen, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Levomilnacipran may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The metabolism of Levomilnacipran can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Medifoxamine is combined with Levomilnacipran.]
[A08AA09, mefenorex, The risk or severity of Tachycardia can be increased when Levomilnacipran is combined with Mefenorex.]
[C07AA14, mepindolol, The serum concentration of Mepindolol can be increased when it is combined with Levomilnacipran.]
[R06AD07, mequitazine, The metabolism of Levomilnacipran can be decreased when combined with Mequitazine.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Levomilnacipran.]
[N04AA03, methixene, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, Levomilnacipran may increase the tachycardic activities of Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Levomilnacipran.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Cyclobarbital is combined with Levomilnacipran.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Melperone is combined with Levomilnacipran.]
[C03AA07, cyclopenthiazide, The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Cyclopenthiazide.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Miglitol.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The metabolism of Levomilnacipran can be increased when combined with Cyclophosphamide.]
[N06AX07, minaprine, Minaprine may increase the serotonergic activities of Levomilnacipran.]
[S01XA18, cyclosporine, The metabolism of Levomilnacipran can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the serotonergic activities of Levomilnacipran.]
[N06BA07, modafinil, The metabolism of Levomilnacipran can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, The therapeutic efficacy of Levomilnacipran can be decreased when used in combination with Cyproheptadine.]
[M02AA02, mofebutazone, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Levomilnacipran can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, Levomilnacipran may increase the tachycardic activities of Moxonidine.]
[M01AH05, etoricoxib, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Etoricoxib.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[G03XA01, danazol, The metabolism of Levomilnacipran can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Levomilnacipran.]
[J04BA02, dapsone, The metabolism of Levomilnacipran can be decreased when combined with Dapsone.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Deanol is combined with Levomilnacipran.]
[C02CC04, debrisoquin, The metabolism of Levomilnacipran can be decreased when combined with Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.]
[M01AX01, nabumetone, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Nabumetone.]
[N07BB05, nalmefene, Nalmefene may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Nordazepam is combined with Levomilnacipran.]
[C07AB12, nebivolol, The serum concentration of Nebivolol can be increased when it is combined with Levomilnacipran.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Levomilnacipran can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Niaprazine is combined with Levomilnacipran.]
[C01DX16, nicorandil, Levomilnacipran may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, The metabolism of Levomilnacipran can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Levomilnacipran.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Levomilnacipran.]
[C01CA05, norfenefrine, Levomilnacipran may increase the tachycardic activities of Norfenefrine.]
[R05DA06, normethadone, The risk or severity of serotonin syndrome can be increased when Normethadone is combined with Levomilnacipran.]
[B01AX05, fondaparinux, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Fondaparinux.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Levomilnacipran is combined with Escitalopram.]
[G04BD08, solifenacin, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Olsalazine.]
[N06AA01, desipramine, The metabolism of Levomilnacipran can be decreased when combined with Desipramine.]
[H01BA02, desmopressin, The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Desmopressin.]
[V04CH02, indigo carmine, Levomilnacipran may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[M01AE12, oxaprozin, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The metabolism of Levomilnacipran can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Levomilnacipran can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Oxiracetam is combined with Levomilnacipran.]
[N04AA08, dexetimide, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Dexfenfluramine is combined with Levomilnacipran.]
[A03AA01, oxyphencyclimine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Levomilnacipran can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Levomilnacipran can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Levomilnacipran.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Levomilnacipran.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Levomilnacipran.]
[N02AC01, dextromoramide, The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Levomilnacipran.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Levomilnacipran.]
[N06AB05, paroxetine, The metabolism of Levomilnacipran can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Levomilnacipran can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of serotonin syndrome can be increased when Diamorphine is combined with Levomilnacipran.]
[C01DA05, pentaerythritol tetranitrate, Pentaerythritol tetranitrate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[P03AC04, permethrin, Permethrin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Levomilnacipran.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Levomilnacipran.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Levomilnacipran.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Dibenzepin is combined with Levomilnacipran.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Levomilnacipran.]
[R05DA08, pholcodine, Levomilnacipran may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Diclofenac.]
[J01CF01, dicloxacillin, The metabolism of Levomilnacipran can be increased when combined with Dicloxacillin.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[A03AA07, dicyclomine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Pipamperone is combined with Levomilnacipran.]
[A03AB14, pipenzolate, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Levomilnacipran.]
[R03CC07, pirbuterol, Levomilnacipran may increase the tachycardic activities of Pirbuterol.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Levomilnacipran.]
[L02AA01, diethylstilbestrol, The metabolism of Levomilnacipran can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Levomilnacipran can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, Levomilnacipran may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Diflunisal.]
[C01AA05, digoxin, The risk or severity of hypotension can be increased when Levomilnacipran is combined with Digoxin.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Levomilnacipran.]
[N02AA03, hydromorphone, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Levomilnacipran.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Levomilnacipran can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Levomilnacipran can be decreased when combined with Treprostinil.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Levomilnacipran.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Pramocaine is combined with Levomilnacipran.]
[C08DB01, diltiazem, The metabolism of Levomilnacipran can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levomilnacipran.]
[V03AB09, dimercaprol, Dimercaprol may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Pridinol is combined with Levomilnacipran.]
[R06AB03, dimethindene, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, Levomilnacipran may increase the tachycardic activities of Procaterol.]
[M02AX03, dimethyl sulfoxide, The metabolism of Levomilnacipran can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Levomilnacipran.]
[N02BB04, propyphenazone, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Proglumetacin.]
[R06AA02, diphenhydramine, The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levomilnacipran.]
[A07DA01, diphenoxylate, The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Levomilnacipran.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quazepam is combined with Levomilnacipran.]
[B01AC07, dipyridamole, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Dipyridamole.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Levomilnacipran.]
[B01AD10, drotrecogin alfa, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Drotrecogin alfa.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Quinupramine is combined with Levomilnacipran.]
[A03FA02, cisapride, The metabolism of Levomilnacipran can be decreased when combined with Cisapride.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Levomilnacipran.]
[R03CC14, reproterol, Levomilnacipran may increase the tachycardic activities of Reproterol.]
[S01AX06, resorcinol, Levomilnacipran may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Levomilnacipran can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Levomilnacipran can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The metabolism of Levomilnacipran can be increased when combined with Rifaximin.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Levomilnacipran.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Levomilnacipran.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Levocetirizine is combined with Levomilnacipran.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Levomilnacipran.]
[L01EX01, sunitinib, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Levomilnacipran can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The metabolism of Levomilnacipran can be decreased when combined with Bortezomib.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[S01BC05, ketorolac, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Ketorolac.]
[C01EB18, ranolazine, The serum concentration of Levomilnacipran can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Salsalate.]
[R03AC12, salmeterol, The metabolism of Levomilnacipran can be decreased when combined with Salmeterol.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Levomilnacipran.]
[C01CA07, dobutamine, Levomilnacipran may increase the tachycardic activities of Dobutamine.]
[A03FA03, domperidone, The metabolism of Levomilnacipran can be decreased when combined with Domperidone.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N06AA16, dothiepin, The metabolism of Levomilnacipran can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of adverse effects can be increased when Doxepin is combined with Levomilnacipran.]
[L01DB01, doxorubicin, The metabolism of Levomilnacipran can be decreased when combined with Doxorubicin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Sertraline is combined with Levomilnacipran.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Levomilnacipran.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Sibutramine is combined with Levomilnacipran.]
[C10AA01, simvastatin, The metabolism of Levomilnacipran can be decreased when combined with Simvastatin.]
[A12CA02, sodium sulfate, Levomilnacipran may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Sultopride is combined with Levomilnacipran.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Levomilnacipran.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Levomilnacipran.]
[H01AA01, corticotropin, The metabolism of Levomilnacipran can be increased when combined with Corticotropin.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Tenoxicam.]
[D01BA02, terbinafine, The metabolism of Levomilnacipran can be decreased when combined with Terbinafine.]
[C07AA16, tertatolol, The serum concentration of Tertatolol can be increased when it is combined with Levomilnacipran.]
[S01GA02, tetrahydrozoline, Levomilnacipran may increase the tachycardic activities of Tetryzoline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Tetrazepam is combined with Levomilnacipran.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Levomilnacipran.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Thiopropazate is combined with Levomilnacipran.]
[G04BD01, emepronium, The risk or severity of adverse effects can be increased when Emepronium is combined with Levomilnacipran.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Tianeptine is combined with Levomilnacipran.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Tofisopam is combined with Levomilnacipran.]
[M01AG02, tolfenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the serotonergic activities of Levomilnacipran.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Levomilnacipran.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[R01AA09, tramazoline, The risk or severity of Tachycardia can be increased when Levomilnacipran is combined with Tramazoline.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Loprazolam is combined with Levomilnacipran.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Levomilnacipran.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Triclofos is combined with Levomilnacipran.]
[A03AB08, tridihexethyl, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[B01AC18, triflusal, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Triflusal.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Levomilnacipran.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Levomilnacipran.]
[N04AA12, tropatepine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[C05CA04, troxerutin, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Troxerutin.]
[R03CC11, tulobuterol, Levomilnacipran may increase the tachycardic activities of Tulobuterol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Levomilnacipran.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Urapidil is combined with Levomilnacipran.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Veralipride is combined with Levomilnacipran.]
[L01CA04, vinorelbine, The metabolism of Levomilnacipran can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, Levomilnacipran may increase the tachycardic activities of Ephedrine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Levomilnacipran.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Levomilnacipran is combined with Venlafaxine.]
[C01CX07, xamoterol, Levomilnacipran may increase the tachycardic activities of Xamoterol.]
[S01GA03, xylometazoline, Levomilnacipran may increase the tachycardic activities of Xylometazoline.]
[C08CA12, mepirodipine, The metabolism of Levomilnacipran can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, Levomilnacipran may increase the tachycardic activities of Epinephrine.]
[N05CF02, zolpidem, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Levomilnacipran.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Insulin glulisine.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Zopiclone is combined with Levomilnacipran.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Zotepine is combined with Levomilnacipran.]
[B01AD03, anistreplase, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Anistreplase.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Levomilnacipran.]
[B01AC11, iloprost, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Iloprost.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Levomilnacipran.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Levomilnacipran.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Levomilnacipran.]
[N02CA02, ergotamine, The metabolism of Levomilnacipran can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Levomilnacipran may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The metabolism of Levomilnacipran can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Levomilnacipran.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[H05BX01, cinacalcet, The metabolism of Levomilnacipran can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Levomilnacipran can be decreased when combined with Estradiol.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The metabolism of Levomilnacipran can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Levomilnacipran can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Levomilnacipran can be decreased when combined with Fluvastatin.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Levomilnacipran is combined with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levomilnacipran.]
[L02AA03, ethinyl estradiol, The metabolism of Levomilnacipran can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N04AA05, profenamine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Levomilnacipran.]
[N03AB01, ethotoin, The metabolism of Levomilnacipran can be increased when combined with Ethotoin.]
[M01AC06, meloxicam, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Levomilnacipran.]
[C01CA01, etilefrine, Levomilnacipran may increase the tachycardic activities of Etilefrine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Levomilnacipran.]
[L01CB01, etoposide, The metabolism of Levomilnacipran can be increased when combined with Etoposide.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Sertindole is combined with Levomilnacipran.]
[L04AD02, tacrolimus, Tacrolimus may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Levomilnacipran.]
[R06AX12, terfenadine, The metabolism of Levomilnacipran can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N06AX12, bupropion, The metabolism of Levomilnacipran can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Levomilnacipran can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The metabolism of Levomilnacipran can be decreased when combined with Encainide.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Levomilnacipran may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Dextran.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C08CA02, felodipine, The metabolism of Levomilnacipran can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Levomilnacipran is combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Fenoprofen.]
[R03CC04, fenoterol, Levomilnacipran may increase the tachycardic activities of Fenoterol.]
[N02AB03, fentanyl, The risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Levomilnacipran.]
[R03CC02, albuterol, Levomilnacipran may increase the tachycardic activities of Salbutamol.]
[B01AD05, plasmin, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Fibrinolysin.]
[L01BB06, clofarabine, Clofarabine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[G04BD02, flavoxate, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Levomilnacipran.]
[N02BG04, floctafenine, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Floctafenine.]
[J01CF05, floxacillin, The metabolism of Levomilnacipran can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The metabolism of Levomilnacipran can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Flunarizine is combined with Levomilnacipran.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Levomilnacipran.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Melitracen is combined with Levomilnacipran.]
[V03AZ01, ethanol, Ethanol can cause an increase in the absorption of Levomilnacipran resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Levomilnacipran.]
[N06AB03, fluoxetine, The serum concentration of Levomilnacipran can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of adverse effects can be increased when Flupentixol is combined with Levomilnacipran.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Levomilnacipran.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Levomilnacipran.]
[S01BC04, flurbiprofen, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Levomilnacipran.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Levomilnacipran.]
[N06BX17, adrafinil, Levomilnacipran may increase the tachycardic activities of Adrafinil.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Alcuronium is combined with Levomilnacipran.]
[G01AX06, furazolidone, Furazolidone may increase the serotonergic activities of Levomilnacipran.]
[J05AE10, darunavir, The metabolism of Levomilnacipran can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Levomilnacipran is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Amisulpride is combined with Levomilnacipran.]
[N06DA04, galantamine, The metabolism of Levomilnacipran can be decreased when combined with Galantamine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Gallamine is combined with Levomilnacipran.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N03AA04, barbexaclone, The metabolism of Levomilnacipran can be increased when combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Bifemelane is combined with Levomilnacipran.]
[C10AB04, gemfibrozil, The metabolism of Levomilnacipran can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, Telavancin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Levomilnacipran.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Liraglutide.]
[J05AG04, etravirine, The metabolism of Levomilnacipran can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Methsuximide is combined with Levomilnacipran.]
[N01AH02, alfentanil, The risk or severity of serotonin syndrome can be increased when Alfentanil is combined with Levomilnacipran.]
[L01EH01, lapatinib, The metabolism of Levomilnacipran can be decreased when combined with Lapatinib.]
[A10BB01, glyburide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Glyburide.]
[A10BB09, gliclazide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Glipizide.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levomilnacipran.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Levomilnacipran.]
[C02CA04, doxazosin, The metabolism of Levomilnacipran can be decreased when combined with Doxazosin.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Levomilnacipran.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Levomilnacipran.]
[C07AB09, esmolol, The serum concentration of Esmolol can be increased when it is combined with Levomilnacipran.]
[M01CB04, aurothioglucose, Levomilnacipran may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Pegaptanib may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Fluindione.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[D01BA01, griseofulvin, The metabolism of Levomilnacipran can be increased when combined with Griseofulvin.]
[S01EX01, guanethidine, Guanethidine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[P01BX01, halofantrine, The metabolism of Levomilnacipran can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Levomilnacipran.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Levomilnacipran.]
[N05AH04, quetiapine, The risk or severity of adverse effects can be increased when Quetiapine is combined with Levomilnacipran.]
[N06BX13, idebenone, Levomilnacipran may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Insulin aspart.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Iprazochrome is combined with Levomilnacipran.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Allobarbital is combined with Levomilnacipran.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C09CA01, losartan, The metabolism of Levomilnacipran can be decreased when combined with Losartan.]
[S01XA14, heparin, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Heparin.]
[G03DC01, allylestrenol, Allylestrenol may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Mesalazine.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Levomilnacipran.]
[R03CC05, hexoprenaline, Levomilnacipran may increase the tachycardic activities of Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Levomilnacipran can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Levomilnacipran can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Nimesulide.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C02DB02, hydralazine, Hydralazine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Levomilnacipran can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Hydroflumethiazide.]
[B05XA17, potassium acetate, Levomilnacipran may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[G04BD06, propiverine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The metabolism of Levomilnacipran can be decreased when combined with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Prothipendyl is combined with Levomilnacipran.]
[B05AA07, hetastarch, Levomilnacipran may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.]
[J04AB04, rifabutin, The metabolism of Levomilnacipran can be increased when combined with Rifabutin.]
[C02AC06, rilmenidine, Levomilnacipran may increase the tachycardic activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Ibuprofen.]
[B05XA08, sodium acetate, Levomilnacipran may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Sodium citrate.]
[L01DB06, idarubicin, The metabolism of Levomilnacipran can be decreased when combined with Idarubicin.]
[L01AA06, ifosfamide, The metabolism of Levomilnacipran can be increased when combined with Ifosfamide.]
[N01AH03, sufentanil, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Levomilnacipran.]
[N06AA02, imipramine, The metabolism of Levomilnacipran can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Levomilnacipran can be increased when combined with Paclitaxel.]
[R01AD07, tixocortol, Levomilnacipran may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Levomilnacipran.]
[L01CE01, topotecan, Topotecan may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C03BA11, indapamide, The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Indapamide.]
[S01BC01, indomethacin, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Indomethacin.]
[A11HA07, inositol, Levomilnacipran may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Milnacipran is combined with Levomilnacipran.]
[A03AA30, piperidolate, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[S01XA28, varenicline, Varenicline may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Articaine is combined with Levomilnacipran.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Sitagliptin.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Levomilnacipran.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Levomilnacipran.]
[R06AE01, buclizine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Vildagliptin.]
[C10AA06, cerivastatin, The metabolism of Levomilnacipran can be increased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Anagrelide.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Levomilnacipran.]
[C03BA02, quinethazone, The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Quinethazone.]
[V03AB01, ipecac, Levomilnacipran may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Iprindole is combined with Levomilnacipran.]
[N06AF05, iproniazid, Iproniazid may increase the serotonergic activities of Levomilnacipran.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Chlorproethazine is combined with Levomilnacipran.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the serotonergic activities of Levomilnacipran.]
[R03CC06, isoetharine, Levomilnacipran may increase the tachycardic activities of Isoetharine.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Levomilnacipran.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Levomilnacipran.]
[J04AC01, isoniazid, The metabolism of Levomilnacipran can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Levomilnacipran may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, Levomilnacipran may increase the tachycardic activities of Isoprenaline.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Exenatide.]
[C01DA14, isosorbide mononitrate, Isosorbide mononitrate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C04AA01, isoxsuprine, Levomilnacipran may increase the tachycardic activities of Isoxsuprine.]
[B01AE06, bivalirudin, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Bivalirudin.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Levomilnacipran.]
[S01AA24, kanamycin, Levomilnacipran may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The metabolism of Levomilnacipran can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Levomilnacipran can be increased when combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Ketanserin is combined with Levomilnacipran.]
[B01AC22, prasugrel, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Levomilnacipran can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Levomilnacipran can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Levomilnacipran.]
[M02AA10, ketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Levomilnacipran can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Levomilnacipran can be increased when combined with Abatacept.]
[C01CA22, arbutamine, Levomilnacipran may increase the tachycardic activities of Arbutamine.]
[N04BC09, rotigotine, Levomilnacipran may increase the sedative activities of Rotigotine.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Levomilnacipran.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The serum concentration of Labetalol can be increased when it is combined with Levomilnacipran.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Levomilnacipran.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Lacosamide is combined with Levomilnacipran.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Levodopa is combined with Levomilnacipran.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Levomilnacipran.]
[S01AA21, amikacin, Levomilnacipran may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Levomilnacipran can be increased when combined with Armodafinil.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Levomilnacipran.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Lofepramine is combined with Levomilnacipran.]
[A07DA03, loperamide, The metabolism of Levomilnacipran can be decreased when combined with Loperamide.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Levomilnacipran.]
[C10AA02, lovastatin, The metabolism of Levomilnacipran can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Levomilnacipran.]
[L01EG01, temsirolimus, The metabolism of Levomilnacipran can be decreased when combined with Temsirolimus.]
[B05XA11, magnesium chloride, Levomilnacipran may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Levomilnacipran may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Levomilnacipran can be increased when used in combination with Magnesium sulfate.]
[L01BA05, pralatrexate, Pralatrexate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Levomilnacipran can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, The risk or severity of adverse effects can be increased when Maprotiline is combined with Levomilnacipran.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Levomilnacipran.]
[C02BB01, mecamylamine, Mecamylamine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Levomilnacipran.]
[M02AA18, meclofenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Medazepam is combined with Levomilnacipran.]
[C01AA08, medigoxin, The risk or severity of hypotension can be increased when Levomilnacipran is combined with Metildigoxin.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Dalteparin.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Levomilnacipran.]
[N06DX01, memantine, Memantine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N02AB02, meperidine, The risk or severity of serotonin syndrome can be increased when Meperidine is combined with Levomilnacipran.]
[C01CA11, mephentermine, Levomilnacipran may increase the tachycardic activities of Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Levomilnacipran.]
[N03AA01, mephobarbital, The metabolism of Levomilnacipran can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Levomilnacipran.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Levomilnacipran.]
[N02AX05, meptazinol, The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Levomilnacipran.]
[G04BX16, tiopronin, Tiopronin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L02BG01, aminoglutethimide, The metabolism of Levomilnacipran can be increased when combined with Aminoglutethimide.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Levomilnacipran.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Paliperidone is combined with Levomilnacipran.]
[C01CA09, metaraminol, Levomilnacipran may increase the tachycardic activities of Metaraminol.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Metformin.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Levomilnacipran.]
[H01CB03, lanreotide, The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Levomilnacipran.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Levomilnacipran.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Metamfetamine is combined with Levomilnacipran.]
[A03AB07, methantheline, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Methapyrilene is combined with Levomilnacipran.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Methaqualone is combined with Levomilnacipran.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Levomilnacipran.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Levomilnacipran which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Metergoline is combined with Levomilnacipran.]
[H03BB02, methimazole, The metabolism of Levomilnacipran can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Levomilnacipran may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Levomilnacipran.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Levomilnacipran.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Ziconotide is combined with Levomilnacipran.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05AA02, methotrimeprazine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, Levomilnacipran may increase the tachycardic activities of Methoxamine.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levomilnacipran.]
[C03AA08, methyclothiazide, The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Methyclothiazide.]
[C02AB01, methyldopa, Levomilnacipran may increase the tachycardic activities of Methyldopa.]
[V04CG05, methylene blue, Levomilnacipran may increase the serotonergic activities of Methylene blue.]
[H02AB04, methylprednisolone, The metabolism of Levomilnacipran can be increased when combined with Methylprednisolone.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Levomilnacipran.]
[G03EK01, methyltestosterone, Methyltestosterone may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Levomilnacipran.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Levomilnacipran.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Levomilnacipran.]
[C03BA08, metolazone, The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Metolazone.]
[C07AB02, metoprolol, The metabolism of Levomilnacipran can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The metabolism of Levomilnacipran can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Levomilnacipran can be increased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Levomilnacipran can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Mianserin is combined with Levomilnacipran.]
[S02AA13, miconazole, The metabolism of Levomilnacipran can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Aminophenazone.]
[B01AB07, parnaparin, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Parnaparin.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Levomilnacipran.]
[C01CA17, midodrine, Levomilnacipran may increase the tachycardic activities of Midodrine.]
[G03XB01, mifepristone, The serum concentration of Levomilnacipran can be increased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Tinzaparin.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.]
[L01XX23, mitotane, The metabolism of Levomilnacipran can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Levomilnacipran.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Levomilnacipran.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C01BD01, amiodarone, The metabolism of Levomilnacipran can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Levomilnacipran.]
[N02AA01, morphine, The risk or severity of serotonin syndrome can be increased when Morphine is combined with Levomilnacipran.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Levomilnacipran.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Levomilnacipran can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Levomilnacipran can be decreased when combined with Eltrombopag.]
[G04BA01, ammonium chloride, Ammonium chloride may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Levomilnacipran.]
[L04AA06, mycophenolic acid, Mycophenolic acid may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Levomilnacipran.]
[N05CA02, amobarbital, The metabolism of Levomilnacipran can be increased when combined with Amobarbital.]
[P01BA06, amodiaquine, The metabolism of Levomilnacipran can be decreased when combined with Amodiaquine.]
[R03BB01, ipratropium bromide, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G03XC01, raloxifene, The metabolism of Levomilnacipran can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Levomilnacipran.]
[N03AB05, fosphenytoin, The metabolism of Levomilnacipran can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, The serum concentration of Nadolol can be increased when it is combined with Levomilnacipran.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N04BC04, ropinirole, Levomilnacipran may increase the sedative activities of Ropinirole.]
[J01CF06, nafcillin, The metabolism of Levomilnacipran can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Naftidrofuryl is combined with Levomilnacipran.]
[N02AF02, nalbuphine, The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Levomilnacipran.]
[V03AB15, naloxone, The metabolism of Levomilnacipran can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Levomilnacipran.]
[L04AC03, anakinra, The metabolism of Levomilnacipran can be increased when combined with Anakinra.]
[S01GA01, naphazoline, Levomilnacipran may increase the tachycardic activities of Naphazoline.]
[N06BA01, amphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Levomilnacipran.]
[M02AA12, naproxen, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Levomilnacipran can be increased when combined with Troglitazone.]
[N06AX21, duloxetine, The metabolism of Levomilnacipran can be decreased when combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Levomilnacipran.]
[S03AA01, neomycin, Levomilnacipran may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of serotonin syndrome can be increased when Remifentanil is combined with Levomilnacipran.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Repaglinide.]
[B01AC17, tirofiban, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Tirofiban.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Iloperidone is combined with Levomilnacipran.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[L03AX16, plerixafor, Plerixafor may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[S01AA23, netilmicin, Levomilnacipran may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Levomilnacipran.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C01CE01, inamrinone, Amrinone may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C10AD02, niacin, The metabolism of Levomilnacipran can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the serotonergic activities of Levomilnacipran.]
[C08CA04, nicardipine, The metabolism of Levomilnacipran can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Levomilnacipran can be decreased when combined with Nicergoline.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Levomilnacipran.]
[C08CA05, nifedipine, The metabolism of Levomilnacipran can be increased when combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Niflumic acid.]
[C08CA07, nisoldipine, Nisoldipine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Nitrazepam is combined with Levomilnacipran.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Levomilnacipran.]
[N04BC05, pramipexole, Levomilnacipran may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Levomilnacipran.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Nomifensine is combined with Levomilnacipran.]
[C01CA03, norepinephrine, Levomilnacipran may increase the tachycardic activities of Norepinephrine.]
[C02KX01, bosentan, The metabolism of Levomilnacipran can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Levomilnacipran.]
[B01AC16, eptifibatide, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Eptifibatide.]
[G02CA02, nylidrin, Levomilnacipran may increase the tachycardic activities of Nylidrin.]
[B01AB08, reviparin, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Reviparin.]
[H01CB02, octreotide, The risk or severity of hypoglycemia can be increased when Octreotide is combined with Levomilnacipran.]
[L04AC04, rilonacept, The metabolism of Levomilnacipran can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Levomilnacipran can be increased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Opipramol is combined with Levomilnacipran.]
[N02AA02, opium, The risk or severity of serotonin syndrome can be increased when Opium is combined with Levomilnacipran.]
[R03CB03, metaproterenol, Levomilnacipran may increase the tachycardic activities of Orciprenaline.]
[B01AD07, reteplase, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Ancrod.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[P02BA02, oxamniquine, The metabolism of Levomilnacipran can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Levomilnacipran.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Levomilnacipran.]
[N02AA05, oxycodone, The risk or severity of serotonin syndrome can be increased when Oxycodone is combined with Levomilnacipran.]
[C01DX03, oxyfedrine, Levomilnacipran may increase the tachycardic activities of Oxyfedrine.]
[S01GA04, oxymetazoline, Levomilnacipran may increase the tachycardic activities of Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of serotonin syndrome can be increased when Oxymorphone is combined with Levomilnacipran.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Oxypertine is combined with Levomilnacipran.]
[S01BC02, oxyphenbutazone, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Asenapine is combined with Levomilnacipran.]
[B01AB09, danaparoid, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Danaparoid.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Levomilnacipran.]
[J04AB30, capreomycin, Levomilnacipran may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[N05CC05, paraldehyde, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[H02AB05, paramethasone, The metabolism of Levomilnacipran can be increased when combined with Paramethasone.]
[C02KC01, pargyline, Pargyline may increase the serotonergic activities of Levomilnacipran.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[G04BD11, fesoterodine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Penbutolol is combined with Levomilnacipran.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Penfluridol is combined with Levomilnacipran.]
[J01CE09, penicillin G procaine, Levomilnacipran may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Levomilnacipran.]
[N05CA01, pentobarbital, The metabolism of Levomilnacipran can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Levomilnacipran may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Pentoxifylline.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Perazine is combined with Levomilnacipran.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Pergolide is combined with Levomilnacipran.]
[C08EX02, perhexiline, The metabolism of Levomilnacipran can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Levomilnacipran.]
[N02BE03, phenacetin, The metabolism of Levomilnacipran can be decreased when combined with Phenacetin.]
[N02AD02, phenazocine, The risk or severity of serotonin syndrome can be increased when Phenazocine is combined with Levomilnacipran.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may increase the serotonergic activities of Levomilnacipran.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Phenformin.]
[B01AA02, phenindione, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Levomilnacipran can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of serotonin syndrome can be increased when Phenoperidine is combined with Levomilnacipran.]
[B01AA04, phenprocoumon, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Phenprocoumon.]
[A08AA01, phentermine, The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Levomilnacipran.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[M02AA01, phenylbutazone, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Phenylbutazone.]
[S01GA05, phenylephrine, Levomilnacipran may increase the tachycardic activities of Phenylephrine.]
[R01BA01, phenylpropanolamine, Levomilnacipran may increase the tachycardic activities of Phenylpropanolamine.]
[N03AB02, phenytoin, The metabolism of Levomilnacipran can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Levomilnacipran can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Levofloxacin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C08CX01, mibefradil, The metabolism of Levomilnacipran can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Levomilnacipran is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Levomilnacipran.]
[C10AA05, atorvastatin, The metabolism of Levomilnacipran can be decreased when combined with Atorvastatin.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Levomilnacipran can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Levomilnacipran can be decreased when combined with Piperazine.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Pipotiazine is combined with Levomilnacipran.]
[N06BX03, piracetam, Levomilnacipran may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[A02BX03, pirenzepine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of serotonin syndrome can be increased when Piritramide is combined with Levomilnacipran.]
[S01BC06, piroxicam, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Piroxicam.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N02CX01, pizotyline, The risk or severity of adverse effects can be increased when Pizotifen is combined with Levomilnacipran.]
[J05AG02, delavirdine, The metabolism of Levomilnacipran can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Levomilnacipran can be decreased when combined with Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Proxibarbal is combined with Levomilnacipran.]
[B01AC13, abciximab, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Abciximab.]
[D05AX05, tazarotene, The metabolism of Levomilnacipran can be decreased when combined with Tazarotene.]
[S01XA13, alteplase, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Alteplase.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Rosiglitazone.]
[L02BG03, anastrozole, The metabolism of Levomilnacipran can be decreased when combined with Anastrozole.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Levomilnacipran.]
[L04AC08, canakinumab, The metabolism of Levomilnacipran can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Levomilnacipran can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Saxagliptin.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Levomilnacipran.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Insulin lispro.]
[C10AA08, pitavastatin, The metabolism of Levomilnacipran can be decreased when combined with Pitavastatin.]
[C07AB01, practolol, The serum concentration of Practolol can be increased when it is combined with Levomilnacipran.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Prazepam is combined with Levomilnacipran.]
[S03BA02, prednisolone, The metabolism of Levomilnacipran can be increased when combined with Prednisolone.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Levomilnacipran.]
[P01BA03, primaquine, The metabolism of Levomilnacipran can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Levomilnacipran can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Levomilnacipran can be increased when combined with Probenecid.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Levomilnacipran.]
[S01HA05, procaine, Procaine may increase the serotonergic activities of Levomilnacipran.]
[L01XB01, procarbazine, Procarbazine may increase the serotonergic activities of Levomilnacipran.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levomilnacipran.]
[N04AA04, procyclidine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Levomilnacipran can be increased when combined with Progesterone.]
[N05AA03, promazine, The risk or severity of adverse effects can be increased when Promazine is combined with Levomilnacipran.]
[R06AD02, promethazine, The risk or severity of adverse effects can be increased when Promethazine is combined with Levomilnacipran.]
[C01BC03, propafenone, The metabolism of Levomilnacipran can be decreased when combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Propanidid is combined with Levomilnacipran.]
[A03AB05, propantheline, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Periciazine is combined with Levomilnacipran.]
[N05CM06, propiomazine, The risk or severity of adverse effects can be increased when Propiomazine is combined with Levomilnacipran.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Levomilnacipran.]
[N02AC04, propoxyphene, The risk or severity of serotonin syndrome can be increased when Dextropropoxyphene is combined with Levomilnacipran.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Levomilnacipran.]
[H03BA02, propylthiouracil, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Levomilnacipran.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Levomilnacipran.]
[B01AC09, epoprostenol, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Epoprostenol.]
[R03DC03, montelukast, The metabolism of Levomilnacipran can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Levomilnacipran.]
[R01BA02, pseudoephedrine, Levomilnacipran may increase the tachycardic activities of Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of adverse effects can be increased when Aripiprazole is combined with Levomilnacipran.]
[N07XX07, dalfampridine, Dalfampridine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[A03AB15, diphemanil, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Levomilnacipran.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Vinbarbital is combined with Levomilnacipran.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Captodiame is combined with Levomilnacipran.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Styramate is combined with Levomilnacipran.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Pyrantel is combined with Levomilnacipran.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Mepyramine is combined with Levomilnacipran.]
[P01BD01, pyrimethamine, The metabolism of Levomilnacipran can be decreased when combined with Pyrimethamine.]
[C01BA01, quinidine, The metabolism of Levomilnacipran can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Levomilnacipran can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Levomilnacipran can be decreased when combined with Ranitidine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Levomilnacipran.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Levomilnacipran can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, Levomilnacipran may increase the tachycardic activities of Rimiterol.]
[G02CA01, ritodrine, Levomilnacipran may increase the tachycardic activities of Ritodrine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Oxitriptan is combined with Levomilnacipran.]
[N02BA05, salicylamide, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Salicylic acid.]
[S01FA02, scopolamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Levomilnacipran.]
[N05CA06, secobarbital, The metabolism of Levomilnacipran can be increased when combined with Secobarbital.]
[N04BD01, selegiline, Selegiline may increase the serotonergic activities of Levomilnacipran.]
[J01GB08, sisomicin, Levomilnacipran may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Levomilnacipran may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Sorbitol may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Levomilnacipran.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Levomilnacipran.]
[C03DA01, spironolactone, The metabolism of Levomilnacipran can be decreased when combined with Spironolactone.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[V09AB03, ioflupane I-123, Levomilnacipran may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.]
[V09AA01, technetium Tc 99m exametazime, Levomilnacipran may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Levomilnacipran.]
[D07AB02, hydrocortisone butyrate, The metabolism of Levomilnacipran can be increased when combined with Hydrocortisone butyrate.]
